StockData
Nektar Therapeutics logo

Nektar Therapeutics (NKTR) stock

NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 10-Q on Nov 13, 2026Score 9/30
$35.91−0.53 (-1.45%)

Close on Nov 17, 2026Market cap $1.23BP/E –Yield –

Nektar Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Nektar Therapeutics's gross margin for the twelve months ending Dec 31, 2025 was 100.0%. For fiscal 2025 it was 100.0%, against 68.8% the year before. The highest annual figure on record is 100.0% in fiscal 2025.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025100.0%+31.2
FY2024Dec 31, 202468.8%+6.3
FY2023Dec 31, 202362.5%−14.0
FY2022Dec 31, 202276.5%+0.9
FY2021Dec 31, 202175.6%−11.7
FY2020Dec 31, 202087.3%+5.9
FY2019Dec 31, 201981.4%−16.6
FY2018Dec 31, 201898.0%+7.9
FY2017Dec 31, 201790.1%+8.3
FY2016Dec 31, 201681.7%−3.5
FY2015Dec 31, 201585.2%−0.6
FY2014Dec 31, 201485.8%+11.6
FY2013Dec 31, 201374.1%+11.6
FY2012Dec 31, 201262.5%−6.9
FY2011Dec 31, 201169.4%−14.5
FY2010Dec 31, 201083.9%+26.9
FY2009Dec 31, 200957.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q4 FY2025Dec 31, 2025100.0%+27.3
Q3 FY2025Sep 30, 2025100.0%+18.4
Q2 FY2025Jun 30, 2025100.0%+41.5
Q1 FY2025Mar 31, 2025100.0%+39.4
Q4 FY2024Dec 31, 202472.7%+3.2
Q3 FY2024Sep 30, 202481.6%+33.1
Q2 FY2024Jun 30, 202458.5%−7.3
Q1 FY2024Mar 31, 202460.6%−6.7
Q4 FY2023Dec 31, 202369.5%−2.2
Q3 FY2023Sep 30, 202348.5%−30.4
Q2 FY2023Jun 30, 202365.9%−10.4
Q1 FY2023Mar 31, 202367.3%−11.3
Q4 FY2022Dec 31, 202271.7%−3.7
Q3 FY2022Sep 30, 202279.0%+0.3
Q2 FY2022Jun 30, 202276.3%+3.4
Q1 FY2022Mar 31, 202278.6%+2.9
Q4 FY2021Dec 31, 202175.4%−6.2
Q3 FY2021Sep 30, 202178.7%−2.8
Q2 FY2021Jun 30, 202172.9%−15.2
Q1 FY2021Mar 31, 202175.7%−16.8
Q4 FY2020Dec 31, 202081.6%−0.7
Q3 FY2020Sep 30, 202081.5%−1.7
Q2 FY2020Jun 30, 202088.2%+9.7
Q1 FY2020Mar 31, 202092.5%+11.7
Q4 FY2019Dec 31, 201982.3%+1.0
Q3 FY2019Sep 30, 201983.1%+0.4
Q2 FY2019Jun 30, 201978.5%−21.0
Q1 FY2019Mar 31, 201980.7%−1.8
Q4 FY2018Dec 31, 201881.3%−8.5
Q3 FY2018Sep 30, 201882.8%−13.5
Q2 FY2018Jun 30, 201899.5%+25.5
Q1 FY2018Mar 31, 201882.5%+7.3
Q4 FY2017Dec 31, 201789.8%+7.4
Q3 FY2017Sep 30, 201796.3%+15.6
Q2 FY2017Jun 30, 201774.0%−2.5
Q1 FY2017Mar 31, 201775.2%–
Q4 FY2016Dec 31, 201682.4%–
Q3 FY2016Sep 30, 201680.6%–
Q2 FY2016Jun 30, 201676.5%–

More Nektar Therapeutics figures

See a number that looks wrong?